JPH11507352A5 - - Google Patents

Info

Publication number
JPH11507352A5
JPH11507352A5 JP1997501850A JP50185097A JPH11507352A5 JP H11507352 A5 JPH11507352 A5 JP H11507352A5 JP 1997501850 A JP1997501850 A JP 1997501850A JP 50185097 A JP50185097 A JP 50185097A JP H11507352 A5 JPH11507352 A5 JP H11507352A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP1997501850A
Other languages
English (en)
Japanese (ja)
Other versions
JPH11507352A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1996/009553 external-priority patent/WO1996040726A1/en
Publication of JPH11507352A publication Critical patent/JPH11507352A/ja
Publication of JPH11507352A5 publication Critical patent/JPH11507352A5/ja
Withdrawn legal-status Critical Current

Links

JP9501850A 1995-06-07 1996-06-05 新規カルバメート基本カチオン性脂質 Withdrawn JPH11507352A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48346595A 1995-06-07 1995-06-07
US08/483,465 1995-06-07
PCT/US1996/009553 WO1996040726A1 (en) 1995-06-07 1996-06-05 Novel carbamate-based cationic lipids

Publications (2)

Publication Number Publication Date
JPH11507352A JPH11507352A (ja) 1999-06-29
JPH11507352A5 true JPH11507352A5 (enExample) 2004-07-29

Family

ID=23920143

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9501850A Withdrawn JPH11507352A (ja) 1995-06-07 1996-06-05 新規カルバメート基本カチオン性脂質

Country Status (6)

Country Link
US (2) US6251939B1 (enExample)
EP (1) EP0830368A1 (enExample)
JP (1) JPH11507352A (enExample)
AU (1) AU701106B2 (enExample)
CA (1) CA2223088A1 (enExample)
WO (1) WO1996040726A1 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU705549B2 (en) * 1995-06-07 1999-05-27 Promega Biosciences, Inc. Phosphonic acid-based cationic lipids
DE69727384T2 (de) * 1996-05-24 2004-11-04 IC-VEC Ltd. Polykatonische sterin-derivate zur transfektion
WO2004089973A2 (en) * 1997-01-23 2004-10-21 Epimmune Inc. Peptides, polypeptides, and proteins of reduced immunogenicity and methods for their production
FR2760193B1 (fr) * 1997-02-28 1999-05-28 Transgene Sa Lipides et complexes de lipides cationiques et de substances actives, notamment pour la transfection de cellules
US5877220A (en) * 1997-03-06 1999-03-02 Genta, Incorporated Amide-based oligomeric cationic lipids
US6034135A (en) * 1997-03-06 2000-03-07 Promega Biosciences, Inc. Dimeric cationic lipids
US5925628A (en) * 1997-03-31 1999-07-20 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US5912239A (en) * 1997-04-04 1999-06-15 Genzyme Corporation Imidazole-containing cationic amphiphiles for intracellular delivery of therapeutic molecules
US5948925A (en) * 1997-05-06 1999-09-07 Genzyme Corporation Cationic amphiphiles containing linkers derived from neutral or positively charged amino acids
US5952516A (en) * 1997-05-08 1999-09-14 Genzyme Corporation Cationic amphiphiles containing multiplesteroid lipophilic groups
US5942634A (en) * 1997-05-09 1999-08-24 Genzyme Corporation Cationic amphiphiles for cell transfections
ATE208369T1 (de) 1997-08-13 2001-11-15 Biontex Lab Gmbh Neue lipopolyamine, deren darstellung und anwendung
JP2003519199A (ja) * 1999-12-30 2003-06-17 ノバルティス アクチエンゲゼルシャフト 遺伝子治療のための新規なコロイド合成ベクター
GB0015624D0 (en) * 2000-06-26 2000-08-16 Nat Cancer Centre Materials and methods relating to improved gene delivery
US6777443B2 (en) * 2001-05-15 2004-08-17 Novartis Ag Dipeptide derivatives
US20040161741A1 (en) * 2001-06-30 2004-08-19 Elazar Rabani Novel compositions and processes for analyte detection, quantification and amplification
US20030153536A1 (en) * 2001-10-25 2003-08-14 Mitchell Glass Compounds and methods of treating transplant rejection
GB0129121D0 (en) * 2001-12-05 2002-01-23 Ic Vec Ltd Compound
CA2491164C (en) 2002-06-28 2012-05-08 Cory Giesbrecht Method and apparatus for producing liposomes
KR101164256B1 (ko) * 2003-09-15 2012-07-10 프로티바 바이오쎄라퓨틱스, 인코포레이티드 폴리에틸렌글리콜 개질된 지질 화합물 및 그의 용도
WO2005121348A1 (en) 2004-06-07 2005-12-22 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
US20060134189A1 (en) * 2004-11-17 2006-06-22 Protiva Biotherapeutics, Inc siRNA silencing of apolipoprotein B
AU2006308765B2 (en) 2005-11-02 2013-09-05 Arbutus Biopharma Corporation Modified siRNA molecules and uses thereof
CA2710713C (en) * 2007-12-27 2017-09-19 Protiva Biotherapeutics, Inc. Silencing of polo-like kinase expression using interfering rna
JP5749494B2 (ja) * 2008-01-02 2015-07-15 テクミラ ファーマシューティカルズ コーポレイション 核酸の送達のための改善された組成物および方法
CN102119217B (zh) 2008-04-15 2015-06-03 普洛体维生物治疗公司 用于核酸递送的新型制剂
EP2326331A4 (en) * 2008-08-18 2013-05-15 Merck Sharp & Dohme NEW LIPID NANOPARTICLES AND NEW COMPONENTS FOR THE RELEASE OF NUCLEIC ACIDS
CA2740000C (en) 2008-10-09 2017-12-12 Tekmira Pharmaceuticals Corporation Improved amino lipids and methods for the delivery of nucleic acids
SG10201901089TA (en) * 2008-11-10 2019-03-28 Arbutus Biopharma Corp Novel lipids and compositions for the delivery of therapeutics
US9023820B2 (en) 2009-01-26 2015-05-05 Protiva Biotherapeutics, Inc. Compositions and methods for silencing apolipoprotein C-III expression
JP5766188B2 (ja) 2009-07-01 2015-08-19 プロチバ バイオセラピューティクス インコーポレイティッド 固形腫瘍に治療剤を送達するための脂質製剤
US9018187B2 (en) 2009-07-01 2015-04-28 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
US8569256B2 (en) 2009-07-01 2013-10-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
US8716464B2 (en) * 2009-07-20 2014-05-06 Thomas W. Geisbert Compositions and methods for silencing Ebola virus gene expression
CA3044884A1 (en) * 2009-12-07 2011-06-16 Arbutus Biopharma Corporation Compositions for nucleic acid delivery
US8455455B1 (en) 2010-03-31 2013-06-04 Protiva Biotherapeutics, Inc. Compositions and methods for silencing genes involved in hemorrhagic fever
US9254327B2 (en) 2010-05-10 2016-02-09 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
WO2011141704A1 (en) * 2010-05-12 2011-11-17 Protiva Biotherapeutics, Inc Novel cyclic cationic lipids and methods of use
JP2013527856A (ja) * 2010-05-12 2013-07-04 プロチバ バイオセラピューティクス インコーポレイティッド 陽イオン性脂質およびその使用方法
WO2012000104A1 (en) 2010-06-30 2012-01-05 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
US8466122B2 (en) 2010-09-17 2013-06-18 Protiva Biotherapeutics, Inc. Trialkyl cationic lipids and methods of use thereof
US9035039B2 (en) 2011-12-22 2015-05-19 Protiva Biotherapeutics, Inc. Compositions and methods for silencing SMAD4
EP3621669B1 (en) 2017-05-11 2023-11-01 Tc1 Llc Thermal interconnect for implantable blood pump
KR20230124927A (ko) 2020-11-25 2023-08-28 아카제라 메디신즈, 인크. 핵산 전달을 위한 지질 나노입자, 및 관련 사용 방법
CA3254658A1 (en) * 2022-04-05 2023-10-12 Capstan Therapeutics, Inc. IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES
US12064479B2 (en) 2022-05-25 2024-08-20 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids and methods of use thereof
WO2024249954A1 (en) 2023-05-31 2024-12-05 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3649674A (en) * 1967-08-25 1972-03-14 Schering Ag Salts of carbamic and thiocarbamic esters with fungicidal and fungistatic action
US4007281A (en) * 1971-04-16 1977-02-08 Colgate-Palmolive Company Pharmaceutical compositions containing quaternary ammonium compounds
ES506955A0 (es) 1980-11-10 1983-02-01 Genentech Inc Un procedimiento para producir un polipeptido antiviral.
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
CA1252778A (en) * 1983-08-25 1989-04-18 Hoffmann-La Roche Limited/Hoffmann-La Roche Limitee Steroids
US4897355A (en) * 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
DE3650699T2 (de) 1985-03-15 1999-04-15 Antivirals Inc., Portland, Oreg. Immunotestmittel für Polynukleotid und Verfahren
ATE105868T1 (de) 1985-09-12 1994-06-15 Scios Nova Inc Rekombinanter fibroblast-wachstumsfaktor.
WO1988001304A1 (en) 1986-08-21 1988-02-25 The Trustees Of Columbia University In The City Of Dna encoding the t cell surface protein t4 and use of fragments of t4 in the treatment of aids
IL87647A0 (en) 1987-09-04 1989-02-28 Biogen Inc Dna sequences,recombinant dna molecules and processes for producing soluble t4 proteins
HUT53672A (en) 1988-02-25 1990-11-28 Gen Hospital Corp Quick immunoselective cloning process
JPH03504496A (ja) * 1988-04-08 1991-10-03 スクリプス　クリニック　アンド　リサーチ　ファウンデーション 水素結合の共有結合置換により安定化されたポリペプチド
JP2826826B2 (ja) * 1988-04-11 1998-11-18 日本ケミファ株式会社 アルキレンジアミン誘導体
US5216141A (en) 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
US4936868A (en) * 1988-07-29 1990-06-26 Shell Oil Company Fuel composition
FR2645866B1 (fr) * 1989-04-17 1991-07-05 Centre Nat Rech Scient Nouvelles lipopolyamines, leur preparation et leur emploi
EP0476071A4 (en) 1989-06-05 1992-11-04 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides and methods for preparing the same
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5399676A (en) 1989-10-23 1995-03-21 Gilead Sciences Oligonucleotides with inverted polarity
KR920702409A (ko) 1989-10-24 1992-09-04 원본미기재 새로운 결합을 갖는 올리고뉴클레오티드 유사체
US5264562A (en) 1989-10-24 1993-11-23 Gilead Sciences, Inc. Oligonucleotide analogs with novel linkages
DK0942000T3 (da) 1989-10-24 2004-11-01 Isis Pharmaceuticals Inc 2'-modificerede oligonukleotider
US5177198A (en) 1989-11-30 1993-01-05 University Of N.C. At Chapel Hill Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
WO1991013080A1 (en) 1990-02-20 1991-09-05 Gilead Sciences, Inc. Pseudonucleosides and pseudonucleotides and their polymers
US5214136A (en) 1990-02-20 1993-05-25 Gilead Sciences, Inc. Anthraquinone-derivatives oligonucleotides
US5470967A (en) 1990-04-10 1995-11-28 The Dupont Merck Pharmaceutical Company Oligonucleotide analogs with sulfamate linkages
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
CA2083719A1 (en) 1990-05-25 1991-11-26 Mark D. Matteucci "sequence-specific non-photoactivated crosslinking agents which bind to the major groove of duplex dna
US5378825A (en) 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
CA2088258C (en) 1990-07-27 2004-09-14 Phillip Dan Cook Nuclease resistant, pyrimidine modified oligonucleotides that detect and modulate gene expression
US5596086A (en) 1990-09-20 1997-01-21 Gilead Sciences, Inc. Modified internucleoside linkages having one nitrogen and two carbon atoms
EP0558634A4 (en) 1990-11-23 1995-06-28 Gilead Sciences Inc Triplex-forming oligomers containing modified bases
IE920562A1 (en) 1991-02-21 1992-08-26 Gilead Sciences Aptamer specific for biomolecules and method of making
DK51092D0 (da) 1991-05-24 1992-04-15 Ole Buchardt Oligonucleotid-analoge betegnet pna, monomere synthoner og fremgangsmaade til fremstilling deraf samt anvendelser deraf
US5283185A (en) * 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
WO1993009127A1 (en) 1991-11-07 1993-05-13 Gilead Sciences, Inc. Enhanced triple-helix formation directed by oligonucleotides composed of 2'-deoxy-7-deazaxanthosine and 2'-deoxy-7-deazaguanosine and related analogs
EP1256589A3 (en) 1991-11-26 2003-09-17 Isis Pharmaceuticals, Inc. Oligomers containing modified pyrimidines
EP0616612A4 (en) 1991-12-12 1995-01-11 Gilead Sciences Inc NUCLEASE-STABLE OLIGOMERS SUITABLE FOR BINDING AND METHODS OF USE.
US5336615A (en) 1992-01-06 1994-08-09 Yale University Genetically engineered endothelial cells exhibiting enhanced migration and plasminogen activator activity
JPH05295017A (ja) * 1992-04-21 1993-11-09 Dai Ichi Kogyo Seiyaku Co Ltd カルバメート基を有する共重合体、その製造方法及び該共重合体を含有する熱可塑性樹脂組成物
WO1993024507A1 (en) 1992-05-28 1993-12-09 Gilead Sciences, Inc. Conformationally restrained oligomers containing amide or carbamate linkages for sequence-specific binding
US5817781A (en) 1992-06-01 1998-10-06 Gilead Sciences, Inc. Modified internucleoside linkages (II)
IL105914A0 (en) 1992-06-04 1993-10-20 Univ California Methods and compositions for in vivo gene therapy
AU4541093A (en) 1992-06-18 1994-01-24 Genpharm International, Inc. Methods for producing transgenic non-human animals harboring a yeast artificial chromosome
US5334761A (en) * 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
AU6014094A (en) 1992-12-02 1994-06-22 Baylor College Of Medicine Episomal vectors for gene therapy
ES2142934T3 (es) * 1993-02-19 2000-05-01 Nippon Shinyaku Co Ltd Derivado del glicerol, dispositivo y composicion farmaceutica.
CA2158148A1 (en) 1993-03-19 1994-09-29 Stephen Charles Inglis Defective mutant non-retroviral virus (e.g. hsv) as vaccine
US5830867A (en) * 1993-05-24 1998-11-03 Smithkline Beecham Corporation Hemoregulatory peptides for stimulating the myelopoietic system

Similar Documents

Publication Publication Date Title
JP2000500033A5 (enExample)
JP2000500445A5 (enExample)
JPH11510317A5 (enExample)
JP2000500440A5 (enExample)
JPH11513378A5 (enExample)
JPH11512785A5 (enExample)
JP2000500627A5 (enExample)
JP2000500145A5 (enExample)
JP2000500406A5 (enExample)
JP2000502389A5 (enExample)
JP2001519678A5 (enExample)
JP2000500361A5 (enExample)
JP2000500115A5 (enExample)
JP2000500342A5 (enExample)
JPH11506914A5 (enExample)
JPH11507352A5 (enExample)
JP2000500112A5 (enExample)
JP2000500226A5 (enExample)
JP2000500051A5 (enExample)
JP2000500407A5 (enExample)
JP2000500397A5 (enExample)
JP2000500019A5 (enExample)
JP2000500125A5 (enExample)
JP2000500044A5 (enExample)
JP2000500346A5 (enExample)